Table of Contents Author Guidelines Submit a Manuscript
Journal of Diabetes Research
Volume 2014 (2014), Article ID 524517, 10 pages
http://dx.doi.org/10.1155/2014/524517
Research Article

The GLP-1 Analogue Exenatide Improves Hepatic and Muscle Insulin Sensitivity in Diabetic Rats: Tracer Studies in the Basal State and during Hyperinsulinemic-Euglycemic Clamp

Institute and Department of Endocrinology and Metabolism, Shanghai Ninth People’s Hospital Affiliated Shanghai Jiaotong University School of Medicine, Shanghai 200011, China

Received 14 August 2014; Revised 17 October 2014; Accepted 18 October 2014; Published 16 November 2014

Academic Editor: Bernard Portha

Copyright © 2014 Hui Wu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Schirra, K. Sturm, P. Leicht, R. Arnold, B. Goke, and M. Katschinski, “Exendin (9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans,” The Journal of Clinical Investigation, vol. 101, no. 7, pp. 1421–1430, 1998. View at Google Scholar
  2. J. Schirra, M. Nicolaus, R. Roggel et al., “Endogenous glucagon-like peptide 1 controls endocrine pancreatic secretion and antro-pyloro-duodenal motility in humans,” Gut, vol. 55, no. 2, pp. 243–251, 2006. View at Publisher · View at Google Scholar · View at Scopus
  3. A. M. Deane, N. Q. Nguyen, J. E. Stevens et al., “Endogenous glucagon-like peptide-1 slows gastric emptying in healthy subjects, attenuating postprandial glycemia,” Journal of Clinical Endocrinology and Metabolism, vol. 95, no. 1, pp. 215–221, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. E. Wajcberg and A. Tavaria, “Exenatide: clinical aspects of the first incretin-mimetic for the treatment of type 2 diabetes mellitus,” Expert Opinion on Pharmacotherapy, vol. 10, no. 1, pp. 135–142, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. D. D. Mafong and R. R. Henry, “Exenatide as a treatment for diabetes and obesity: implications for cardiovascular risk reduction,” Current Atherosclerosis Reports, vol. 10, no. 1, pp. 55–60, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. C. M. Edwards, S. A. Stanley, R. Davis et al., “Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers,” The American Journal of Physiology—Endocrinology and Metabolism, vol. 281, no. 1, pp. E155–E161, 2001. View at Google Scholar · View at Scopus
  7. L. Arnés, N. González, P. Tornero-Esteban et al., “Characteristics of GLP-1 and exendins action upon glucose transport and metabolism in type 2 diabetic rat skeletal muscle,” International Journal of Molecular Medicine, vol. 22, no. 1, pp. 127–132, 2008. View at Google Scholar · View at Scopus
  8. Y. Bi, M. Cai, H. Liang et al., “Increased carnitine palmitoyl transferase 1 expression and decreased sterol regulatory element-binding protein 1c expression are associated with reduced intramuscular triglyceride accumulation after insulin therapy in high-fat-diet and streptozotocin-induced diabetic rats,” Metabolism: Clinical and Experimental, vol. 58, no. 6, pp. 779–786, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. Z. Guo and L. Zhou, “Dual tail catheters for infusion and sampling in rats as an efficient platform for metabolic experiments,” Lab Animal, vol. 32, no. 2, pp. 45–48, 2003. View at Publisher · View at Google Scholar · View at Scopus
  10. D. T. Mahin and R. T. Lofberg, “A simplified method of sample preparation for determination of tritium, carbon-14, or sulfur-35 in blood or tissue by liquid scintillation counting,” Analytical Biochemistry, vol. 16, no. 3, pp. 500–509, 1966. View at Publisher · View at Google Scholar · View at Scopus
  11. A. Vella and R. A. Rizza, “Application of isotopic techniques using constant specific activity or enrichment to the study of carbohydrate metabolism,” Diabetes, vol. 58, no. 10, pp. 2168–2174, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. O. Peroni, V. Large, and M. Beylot, “Measuring gluconeogenesis with [2–13C]glycerol and mass isotopomer distribution analysis of glucose,” The American Journal of Physiology—Endocrinology and Metabolism, vol. 269, no. 3, pp. E516–E523, 1995. View at Google Scholar · View at Scopus
  13. Z. Guo and L. Zhou, “Muscle type-dependent responses to insulin in intramyocellular triglyceride turnover in obese rats,” Obesity Research, vol. 13, no. 12, pp. 2081–2087, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. E. W. Kraegen, D. E. James, S. P. Bennett, and D. J. Chisholm, “In vivo insulin sensitivity in the rat determined by euglycemic clamp,” The American Journal of Physiology, vol. 245, no. 1, pp. E1–E7, 1983. View at Google Scholar · View at Scopus
  15. Z. Guo and M. D. Jensen, “Blood glycerol is an important precursor for intramuscular triacylglycerol synthesis,” Journal of Biological Chemistry, vol. 274, no. 34, pp. 23702–23706, 1999. View at Publisher · View at Google Scholar · View at Scopus
  16. H. Wu, F.-Z. Xia, H. Xu et al., “Acute effects of different glycemic index diets on serum motilin, orexin and neuropeptide Y concentrations in healthy individuals,” Neuropeptides, vol. 46, no. 3, pp. 113–118, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. D. P. Bradley, R. Kulstad, and D. A. Schoeller, “Exenatide and weight loss,” Nutrition, vol. 26, no. 3, pp. 243–249, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Vaughan, “The production and release of glycerol by adipose tissue incubated in vitro,” The Journal of Biological Chemistry, vol. 237, pp. 3354–3358, 1962. View at Google Scholar · View at Scopus
  19. G. Boden, “Obesity, insulin resistance and free fatty acids,” Current Opinion in Endocrinology, Diabetes and Obesity, vol. 18, no. 2, pp. 139–143, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. D. C. Klonoff, J. B. Buse, L. L. Nielsen et al., “Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years,” Current Medical Research and Opinion, vol. 24, no. 1, pp. 275–286, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. D. Zheng, V. Ionut, V. Mooradian, D. Stefanovski, and R. N. Bergman, “Exenatide sensitizes insulin-mediated whole-body glucose disposal and promotes uptake of exogenous glucose by the liver,” Diabetes, vol. 58, no. 2, pp. 352–359, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. R. Basu, W. F. Schwenk, and R. A. Rizza, “Both fasting glucose production and disappearance are abnormal in people with “mild” and “severe” type 2 diabetes,” American Journal of Physiology: Endocrinology and Metabolism, vol. 287, no. 1, pp. E55–E62, 2004. View at Publisher · View at Google Scholar · View at Scopus
  23. B. R. Landau, J. Wahren, V. Chandramouli, W. C. Schumann, K. Ekberg, and S. C. Kalhan, “Contributions of gluconeogenesis to glucose production in the fasted state,” The Journal of Clinical Investigation, vol. 98, no. 2, pp. 378–385, 1996. View at Publisher · View at Google Scholar · View at Scopus
  24. D. L. Rothman, I. Magnusson, L. D. Katz, R. G. Shulman, and G. I. Shulman, “Quantitation of hepatic glycogenolysis and gluconeogenesis in fasting humans with 13C NMR,” Science, vol. 254, no. 5031, pp. 573–576, 1991. View at Publisher · View at Google Scholar · View at Scopus
  25. R. A. DeFronzo and D. Tripathy, “Skeletal muscle insulin resistance is the primary defect in type 2 diabetes,” Diabetes Care, vol. 32, supplement 2, pp. S157–S163, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. S. Lillioja, D. M. Mott, B. V. Howard et al., “Impaired glucose tolerance as a disorder of insulin action. Longitudinal and cross-sectional studies in Pima Indians,” The New England Journal of Medicine, vol. 318, no. 19, pp. 1217–1225, 1988. View at Publisher · View at Google Scholar · View at Scopus
  27. J. H. Warram, B. C. Martin, A. S. Krolewski, J. S. Soeldner, and C. R. Kahn, “Slow glucose removal rate and hyperinsulinemia precede the development of type II diabetes in the offspring of diabetic parents,” Annals of Internal Medicine, vol. 113, no. 12, pp. 909–915, 1990. View at Publisher · View at Google Scholar · View at Scopus
  28. E. Ferrannini, D. C. Simonson, L. D. Katz et al., “The disposal of an oral glucose load in patients with non-insulin-dependent diabetes,” Metabolism, vol. 37, no. 1, pp. 79–85, 1988. View at Publisher · View at Google Scholar · View at Scopus
  29. D. Thiebaud, E. Jacot, R. A. DeFronzo, E. Maeder, E. Jequier, and J. P. Felber, “The effect of graded doses of insulin on total glucose uptake, glucose oxidation, and glucose storage in man,” Diabetes, vol. 31, no. 11, pp. 957–963, 1982. View at Publisher · View at Google Scholar · View at Scopus